Matrix metalloproteinase-responsive micellar systems for cancer therapy: Design principles, preclinical evidence, and translational challenges.
文献摘要
Matrix metalloproteinase (MMP)-responsive micelles are tumor-microenvironment-activated drug-delivery systems designed to convert local proteolytic activity into controlled carrier transformation or payload release. In these platforms, MMPs are not structural components of the micelle; rather, active enzymes cleave incorporated peptide linkers, coatings, prodrug bonds, or degradable matrices to trigger drug release, PEG deshielding, ligand exposure, charge or size transformation, micelle-to-fibre transition, local depot degradation, or enhanced cellular uptake. This review critically evaluates MMP-responsive micellar systems for cancer therapy by linking MMP biology with micellar architecture, payload design, activation mechanism, preclinical performance, and translational barriers. Conventional, reverse, unimolecular, mixed, and polyion complex micelles are first compared to establish the formulation principles underlying responsive delivery. The roles of MMPs in tumor invasion, stromal remodeling, biomarker detection, direct inhibition, and enzyme-triggered carrier activation are then discussed. Representative MMP-responsive micelles for chemotherapy, siRNA delivery, metastasis suppression, local therapy, and chemoimmunotherapy are analyzed with attention to cleavage mechanism, biological model, therapeutic outcome, and control design. Although preclinical studies demonstrate improved tumor accumulation, penetration, cellular uptake, drug release, antitumor efficacy, and reduced systemic toxicity in selected models, translation remains limited by heterogeneous MMP activity, substrate cross-reactivity, off-tumor protease activation, micellar instability, premature leakage, manufacturing complexity, and incomplete safety assessment. Future progress will require active-enzyme quantification, validated peptide specificity, non-cleavable and non-responsive controls, patient-relevant models, scalable manufacturing, and companion diagnostic strategies.